
Supplementary material

Supplementary Figure 1 (S1).

Trans-bronchial biopsyprior tobenralizumab treatment showing eosinophil infiltration at the capillary wall (black arrows - A) and immune-histochemical analysis with an anti-IL- $5R\alpha$ polyclonal antibody showing positive staining of submucosal infiltrating eosinophils (black arrows - B). Trans-bronchial biopsy after benralizumab treatment with no eosinophilic vasculitis (C) and immune-histochemical analysis confirming the absence of IL- $5R\alpha$ -positive cells (D).



J Investig Allergol Clin Immunol 2021; Vol. 31(6) doi: 10.18176/jiaci.0689